Session » Abstracts: Interprofessional Exemplary

Date: Monday, November 13, 2023

Time: 2:00PM-3:30PM

Meeting: ACR Convergence 2023

Abstract Number: 1651

Beneficial Effect of Temporary Methotrexate Interruption on B and T Cell Responses upon SARSCoV-2 Vaccination in Patients with Rheumatoid Arthritis or Psoriatic Arthritis

Abstract Number: 1652

Lupus Research Action Network: Increasing Minority Clinical Trial Participation Through Peer Leaders

Abstract Number: 1653

Up or Down: Does Direction of Stair Climbing Difficulty Matter for Incident Functional Limitation and Knee Replacement in Knee Osteoarthritis?

Abstract Number: 1654

A Peer Health Coached Resilience-Based Energy Management Program Was Effective in Improving Fatigue and Other Outcomes in People with Systemic Sclerosis: Results of a Randomized Controlled Trial

Abstract Number: 1655

Usability Testing of JIActiv, an Instagram-Based Program Promoting Engagement in Physical Activity Among Young People Living with Juvenile Idiopathic Arthritis

Abstract Number: 1656

Nothing About Us Without Us: Top 10 Research Priorities from Patients – A James Lind Alliance Project for Public and Patient Involvement (PPI)

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.